Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. AB Science
WARNING LETTER
•AB Science

AB Science – FDA Warning Letter

Record Details

The FDA Center for Veterinary Medicine (CVM) issued a Warning Letter to AB Science regarding promotional materials for Kinavet-CA1 (masitinib mesylate) found on its website and in submitted documents. The FDA determined these materials promote Kinavet-CA1 for unapproved new uses, lack adequate directions for use, omit critical effectiveness information, and minimize associated risks. Consequently, Kinavet-CA1 is deemed unsafe, adulterated, and misbranded under the Federal Food, Drug, and Cosmetic Act (FD&C Act), violating 21 U.S.C. ?? 360b, 351(a)(5), 352(f), 331(a), 352(a), and 352(n). Specifically, the promotional content suggests Kinavet-CA1 is effective for a broader range of indications than its conditional approval for canine mast cell tumors, including canine atopic dermatitis, feline oncological/inflammatory diseases, and various other cancers and immune-mediated disorders. The letter emphasizes that extra-label use of conditionally approved drugs is prohibited. Furthermore, the materials fail to disclose that the drug's effectiveness has not been established and omit crucial human warning information and detailed adverse reactions for treated dogs, instead presenting the drug as "safe" and "generally well tolerated." These omissions and minimizations violate 21 CFR 202.1(e)(1) and 202.1(e)(6)(i). AB Science is required to immediately cease misbranding Kinavet-CA1 and introducing it into interstate commerce for unapproved uses. A written response detailing corrective actions, including discontinuing violative materials or ceasing drug distribution, is mandated within 15 calendar days. Failure to comply may lead to enforcement actions such as seizure and injunction.

Company
AB Science
Product type
Veterinary
Office
Center for Veterinary Medicine
People
  • Neal Bataller (Division Director)
  • Michael R. Langley (Senior Pharmaceutical)
View Company Profile

ID · 9f221853-def6-4e0f-ab5d-b24213aa9677

Violation Codes10
21 U.S.C. 360b21 U.S.C. 351(a)(5)21 U.S.C. 352(f)21 U.S.C. 352(a)21 U.S.C. 352(n)21 U.S.C. 360ccc21 U.S.C. 360b(a)21 U.S.C. 360b(a)(4)21 U.S.C. 360b(b)21 CFR 202.1

Full citation text and observation details available on the Dashboard.

Other documents for AB Science
  • EIR - 2014-09-26September 26, 2014
  • WARNING_LETTER - 2014-09-26September 26, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AB Science
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.